Debabrata Mukherjee

Debabrata Mukherjee

Auto-generated profile, based on publicly available information

Debabrata Mukherjee

Division of Cardiovascular Medicine, Texas Tech University Health Sciences Center, El Paso

Research Focus & Metrics

Academic Career Length

37Years (1990-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 August 2015 in European Heart Journal
Verified
Journal Article
Open access
PDF file
MRMarco Roffi
Marco Roffi
CPCarlo Patrono
Carlo Patrono
JCJean-Philippe Collet
Jean-Philippe Collet
CMChristian Müller
Christian Müller
MVMarco Valgimigli
Marco Valgimigli
SWStephan Windecker
Stephan Windecker
Guidelines summarize and evaluate all available evidence on a particular issue at the time of the writing process, with the aim of assisting health professionals in selecting the best management strategies for an individual patient with a given condition, taking into account the impact on outcome, as well as the risk–benefit ratio of particular diagnostic or therapeutic means. Guidelines and recommendations should help health professionals to make decisions in their daily practice. However, the final decisions concerning an individual patient must be made by the responsible health professional(s) in consultation with the patient and caregiver as appropriate.

1 December 2011 in JACC
Verified
Journal Article
Closed access
GLGlenn N. Levine
Glenn N. Levine
EBEric R. Bates
Eric R. Bates
JBJames C. Blankenship
James C. Blankenship
SBSteven R. Bailey
Steven R. Bailey
JBJohn A. Bittl
John A. Bittl
HTHenry H. Ting
Henry H. Ting


22 August 2001 in JAMA
Verified
Journal Article
Closed access
PDF file
DMDebabrata Mukherjee
Debabrata Mukherjee
SNSteven E. Nissen
Steven E. Nissen
ETEric J. Topol
Eric J. Topol
Atherosclerosis is a process with inflammatory features and selective cyclooxygenase 2 (COX-2) inhibitors may potentially have antiatherogenic effects by virtue of inhibiting inflammation. However, by decreasing vasodilatory and antiaggregatory prostacyclin production, COX-2 antagonists may lead to increased prothrombotic activity. To define the cardiovascular effects of COX-2 inhibitors when used for arthritis and musculoskeletal pain in patients without coronary artery disease, we performed a MEDLINE search to identify all English-language articles on use of COX-2 inhibitors published between 1998 and February 2001. We also reviewed relevant submissions to the US Food and Drug Administration by pharmaceutical companies.Our search yielded 2 major randomized trials, the Vioxx Gastrointestinal Outcomes Research Study (VIGOR; 8076 patients) and the Celecoxib Long-term Arthritis Safety Study (CLASS; 8059 patients), as well as 2 smaller trials with approximately 1000 patients each. The results from VIGOR showed that the relative risk of developing a confirmed adjudicated thrombotic cardiovascular event (myocardial infarction, unstable angina, cardiac thrombus, resuscitated cardiac arrest, sudden or unexplained death, ischemic stroke, and transient ischemic attacks) with rofecoxib treatment compared with naproxen was 2.38 (95% confidence interval, 1.39-4.00; P = .002). There was no significant difference in cardiovascular event (myocardial infarction, stroke, and death) rates between celecoxib and nonsteroidal anti-inflammatory agents in CLASS. The annualized myocardial infarction rates for COX-2 inhibitors in both VIGOR and CLASS were significantly higher than that in the placebo group of a recent meta-analysis of 23 407 patients in primary prevention trials (0.52%): 0.74% with rofecoxib (P = .04 compared with the placebo group of the meta-analysis) and 0.80% with celecoxib (P = .02 compared with the placebo group of the meta-analysis).The available data raise a cautionary flag about the risk of cardiovascular events with COX-2 inhibitors. Further prospective trial evaluation may characterize and determine the magnitude of the risk.

6 December 2011 in Circulation
Verified
Journal Article
Closed access
GLGlenn N Levine
Glenn N Levine
EBEric R Bates
Eric R Bates
JBJames C Blankenship
James C Blankenship
SBSteven R Bailey
Steven R Bailey
JBJohn A Bittl
John A Bittl
HTHenry H Ting
Henry H Ting

1 December 2014 in Circulation
Verified
Journal Article
Closed access
PDF file
EAEzra A. Amsterdam
Ezra A. Amsterdam
NWNanette K. Wenger
Nanette K. Wenger
RBRalph G. Brindis
Ralph G. Brindis
DCDonald E. Casey
Donald E. Casey
TGTheodore G. Ganiats
Theodore G. Ganiats
SZSusan J. Zieman
Susan J. Zieman